glycine has been researched along with Intraocular Pressure in 27 studies
Intraocular Pressure: The pressure of the fluids in the eye.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We explored the melatonin influence on the level of amino acid neurotransmitters of the retina in glaucoma neuropathy in rats." | 7.79 | [Protective action of melatonin in experimental glaucoma in rats]. ( Mykheĭtseva, IM, 2013) |
| "Retinal ischemia increased vitreous concentrations of glutamate and glycine." | 7.70 | Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. ( Bach, M; Feuerstein, TJ; Knörle, R; Lagrèze, WA, 1998) |
| "We explored the melatonin influence on the level of amino acid neurotransmitters of the retina in glaucoma neuropathy in rats." | 3.79 | [Protective action of melatonin in experimental glaucoma in rats]. ( Mykheĭtseva, IM, 2013) |
| "Amacrine cells identified by GABA and glycine labeling were not significantly affected by experimental glaucoma, with a mean decrease of 15% compared with bilaterally untreated control cells (557 +/- 186 neurons/mm [glaucoma] versus 653." | 3.73 | The effect of experimental glaucoma and optic nerve transection on amacrine cells in the rat retina. ( Kielczewski, JL; Pease, ME; Quigley, HA, 2005) |
| "An inner retinal component removed by GABA and glycine was found in both the normal and glaucomatous eyes." | 3.72 | Functional damage to inner and outer retinal cells in experimental glaucoma. ( Lambrou, GN; Ofri, R; Percicot, CL; Perlman, I; Raz, D, 2003) |
| "Retinal ischemia increased vitreous concentrations of glutamate and glycine." | 3.70 | Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. ( Bach, M; Feuerstein, TJ; Knörle, R; Lagrèze, WA, 1998) |
| " Most adverse events (AEs) were mild, and no serious treatment-related AEs were reported." | 3.01 | Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. ( Aihara, M; Iwata, A; Kawata, H; Lu, F; Odani-Kawabata, N, 2021) |
| " However, adverse events (AEs) were higher in the BID arm; thus, QD dosing is the preferred dosing frequency for further investigation." | 3.01 | A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6). ( Abrams, MA; Chabi, A; Dinh, P; Jerkins, GW; Lu, F; Odani-Kawabata, N; Olander, KW; Sato, MA; Shams, NK, 2021) |
| "Patients with glaucoma and ocular hypertension (OH) with no previous history of OMDI use were enrolled." | 1.72 | Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan. ( Kuwayama, Y; Nakazawa, T; Nomura, A; Shimada, F; Takahashi, K, 2022) |
| " The main outcome measures were the change in intraocular pressure (IOP) at week 4 and week 12 after the initiation of OMDI treatment, and frequency of adverse drug reactions." | 1.72 | Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan. ( Hori, K; Ishida, N; Miki, A; Miyamoto, E; Shii, D, 2022) |
| "Decreased vision and cystoid macular edema (CME) developed in phakic eyes of a patient who underwent laser iridotomy after changing the glaucoma eye drops from carteolol 2% long-acting ophthalmic solution to omidenepag isopropyl 0." | 1.62 | Cystoid Macular Edema Associated with Omidenepag Isopropyl in Phakic Eyes after Laser Iridotomy: A Case Report. ( Igarashi, T; Nakamoto, K; Nishio, Y; Shiratori, N; Sugimoto, S; Takahashi, H; Takano, Y; Tobita, Y; Yamazaki, M, 2021) |
| " In a crossover manner, the hypertensive eye of each monkey was dosed once daily with 20 μL of either 0." | 1.48 | Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. ( Fan, S; Fuwa, M; Ichikawa, M; Iwamura, R; Matsugi, T; Odani-Kawabata, N; Shams, NK; Taniguchi, T; Toris, CB; Yoneda, K; Zhang, JZ, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.11) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 6 (22.22) | 29.6817 |
| 2010's | 5 (18.52) | 24.3611 |
| 2020's | 12 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Aihara, M | 5 |
| Lu, F | 6 |
| Kawata, H | 5 |
| Iwata, A | 4 |
| Odani-Kawabata, N | 8 |
| Inoue, K | 2 |
| Shiokawa, M | 2 |
| Katakura, S | 1 |
| Tsuruoka, M | 1 |
| Kunimatsu-Sanuki, S | 2 |
| Shimizu, K | 2 |
| Ishida, K | 2 |
| Tomita, G | 2 |
| Nakazawa, T | 1 |
| Takahashi, K | 1 |
| Kuwayama, Y | 1 |
| Nomura, A | 1 |
| Shimada, F | 1 |
| Miki, A | 1 |
| Miyamoto, E | 1 |
| Ishida, N | 1 |
| Shii, D | 1 |
| Hori, K | 1 |
| Nozaki, N | 1 |
| Tanaka, Y | 1 |
| Yamamura, K | 1 |
| Shams, NK | 6 |
| Nakakura, S | 2 |
| Terao, E | 1 |
| Fujisawa, Y | 1 |
| Tabuchi, H | 1 |
| Kiuchi, Y | 1 |
| Ropo, A | 1 |
| Shams, N | 1 |
| Kanamori, A | 1 |
| Fukuma, Y | 1 |
| Wakabayashi, S | 1 |
| Nagata, Y | 1 |
| Adachi, M | 1 |
| Fuwa, M | 2 |
| Shimazaki, A | 1 |
| Kirihara, T | 1 |
| Taniguchi, T | 2 |
| Iwamura, R | 2 |
| Yoneda, K | 2 |
| Kato, M | 1 |
| Morishima, K | 1 |
| Nakamoto, K | 1 |
| Shiratori, N | 1 |
| Nishio, Y | 1 |
| Sugimoto, S | 1 |
| Takano, Y | 1 |
| Yamazaki, M | 1 |
| Tobita, Y | 1 |
| Igarashi, T | 1 |
| Takahashi, H | 1 |
| Olander, KW | 1 |
| Sato, MA | 1 |
| Abrams, MA | 1 |
| Jerkins, GW | 1 |
| Dinh, P | 1 |
| Chabi, A | 1 |
| Toris, CB | 1 |
| Fan, S | 1 |
| Ichikawa, M | 1 |
| Matsugi, T | 1 |
| Zhang, JZ | 1 |
| Liu, K | 1 |
| Caldwell, MD | 1 |
| Hu, SS | 1 |
| Viswanathan, S | 1 |
| Bradshaw, H | 1 |
| Kelly, ME | 1 |
| Straiker, A | 1 |
| Mykheĭtseva, IM | 1 |
| Raz, D | 1 |
| Perlman, I | 1 |
| Percicot, CL | 1 |
| Lambrou, GN | 1 |
| Ofri, R | 1 |
| Kielczewski, JL | 1 |
| Pease, ME | 1 |
| Quigley, HA | 1 |
| Veselovský, J | 3 |
| Oláh, Z | 3 |
| Veselá, A | 2 |
| Gressnerová, S | 2 |
| Roe, RH | 1 |
| Fisher, Y | 1 |
| Eagle, RC | 1 |
| Fine, HF | 1 |
| Cunningham, ET | 1 |
| Lagrèze, WA | 1 |
| Knörle, R | 1 |
| Bach, M | 1 |
| Feuerstein, TJ | 1 |
| Fox, SL | 1 |
| Krantz, JC | 1 |
| Helmsen, RJ | 1 |
| Gaasterland, DE | 1 |
| Rubin, M | 1 |
| Hara, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Long-term Open-label Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension : RENGE Study[NCT02822729] | Phase 3 | 125 participants (Actual) | Interventional | 2016-07-01 | Completed | ||
| A Phase II/III Randomized, Double-masked, Controlled, Parallel Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-[NCT02623738] | Phase 2/Phase 3 | 253 participants (Actual) | Interventional | 2015-12-06 | Completed | ||
| A Phase III, Open-label, Single-arm, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension Who Are Non-/Low-responders to Latanoprost Ophthalmic Solution: FUJ[NCT02822742] | Phase 3 | 26 participants (Actual) | Interventional | 2016-07-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for glycine and Intraocular Pressure
| Article | Year |
|---|---|
Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
Topics: Antihypertensive Agents; Double-Blind Method; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pre | 2021 |
Periocular Adverse Reactions to Omidenepag Isopropyl.
Topics: Antihypertensive Agents; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pressure; Ocular Hyperte | 2022 |
Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
Topics: Adult; Drug-Related Side Effects and Adverse Reactions; Glycine; Healthy Volunteers; Humans; Intraoc | 2019 |
Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
Topics: Dose-Response Relationship, Drug; Female; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pressur | 2020 |
Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Topics: Administration, Ophthalmic; Aged; Antihypertensive Agents; Female; Glaucoma, Open-Angle; Glycine; Hu | 2020 |
A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).
Topics: Antihypertensive Agents; Double-Blind Method; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pre | 2021 |
Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Topics: Aged; Antihypertensive Agents; Corneal Pachymetry; Dose-Response Relationship, Drug; Double-Blind Me | 2019 |
20 other studies available for glycine and Intraocular Pressure
| Article | Year |
|---|---|
Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
Topics: Antihypertensive Agents; Glaucoma; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pressure; Japa | 2022 |
Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
Topics: Antihypertensive Agents; Drug-Related Side Effects and Adverse Reactions; Glaucoma; Glaucoma, Open-A | 2022 |
One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma.
Topics: Glycine; Humans; Intraocular Pressure; Low Tension Glaucoma; Pyrazoles; Pyridines; Retrospective Stu | 2022 |
Changes in Prostaglandin-associated Periorbital Syndrome After Switch from Conventional Prostaglandin F2α Treatment to Omidenepag Isopropyl in 11 Consecutive Patients.
Topics: Aged; Antihypertensive Agents; Bimatoprost; Drug Substitution; Eyelid Diseases; Female; Glycine; Hum | 2020 |
Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study.
Topics: Antihypertensive Agents; Female; Glaucoma; Glycine; Humans; Intraocular Pressure; Japan; Male; Medic | 2021 |
Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Animals; | 2021 |
Cystoid Macular Edema Associated with Omidenepag Isopropyl in Phakic Eyes after Laser Iridotomy: A Case Report.
Topics: Cataract Extraction; Glycine; Humans; Intraocular Pressure; Lasers; Macular Edema; Middle Aged; Opht | 2021 |
Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.
Topics: Administration, Topical; Animals; Aqueous Humor; Dose-Response Relationship, Drug; Female; Glycine; | 2018 |
A GPR18-based signalling system regulates IOP in murine eye.
Topics: Administration, Ophthalmic; Animals; Anterior Eye Segment; Arachidonic Acids; Cannabinoid Receptor A | 2013 |
[Protective action of melatonin in experimental glaucoma in rats].
Topics: Animals; Antioxidants; Aspartic Acid; Chromatography, Ion Exchange; Epinephrine; gamma-Aminobutyric | 2013 |
Functional damage to inner and outer retinal cells in experimental glaucoma.
Topics: Aminobutyrates; Animals; Electroretinography; gamma-Aminobutyric Acid; Glaucoma; Glycine; Interneuro | 2003 |
The effect of experimental glaucoma and optic nerve transection on amacrine cells in the rat retina.
Topics: Amacrine Cells; Animals; Axons; Cell Count; Disease Models, Animal; gamma-Aminobutyric Acid; Glaucom | 2005 |
[The effect of glycine with timoptol on the rabbit IOP physiological values].
Topics: Adrenergic beta-Antagonists; Animals; Drug Combinations; Glycine; Intraocular Pressure; Ophthalmic S | 2006 |
[Changes of the physiological intraocular pressure (IOP) values after the application of latanoprost and amino acid glycine mixture in rabbits].
Topics: Animals; Antihypertensive Agents; Drug Combinations; Female; Glycine; Intraocular Pressure; Latanopr | 2007 |
Rabbit's intraocular pressure after instillation of timolol and aminoacid lysine, arginine, glycine or taurine mixture.
Topics: Amino Acids; Animals; Arginine; Drug Combinations; Female; Glaucoma; Glycine; Intraocular Pressure; | 2007 |
Oculoleptomeningeal amyloidosis in a patient with a TTR Val30Gly mutation in the transthyretin gene.
Topics: Adult; Amyloid; Amyloid Neuropathies, Familial; DNA Mutational Analysis; Eye Diseases; Glycine; Huma | 2007 |
Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia.
Topics: Animals; Cell Count; Chromatography, High Pressure Liquid; Disease Models, Animal; Excitatory Amino | 1998 |
The use of glycine in the reduction of intraocular pressure.
Topics: Animals; Glaucoma; Glycine; Humans; Intraocular Pressure; Male; Rabbits | 1972 |
Induction of buphthalmos in chicks fed an excess of glycine.
Topics: Animals; Aqueous Humor; Chickens; Diet; Eye; Female; Gelatin; Glaucoma; Glycine; Hydrophthalmos; Int | 1973 |
[Studies on the histological adaptability of substitute of the vitreous body. 2].
Topics: Animals; Ciliary Body; Glucosamine; Glucuronates; Glycine; Hyaluronic Acid; Intraocular Pressure; Pr | 1971 |